Cytokinetics gets up to $675m in expanded Astellas deal
This article was originally published in Scrip
Executive Summary
Cytokinetics may earn up to $675m in upfront, milestone and other fees from Astellas after the companies expanded their skeletal muscle activator collaboration to advance CK-2127107 in spinal muscular atrophy (SMA) and other neuromuscular indications.
You may also be interested in...
Astellas Targets ALS In Expansion Of Cytokinetics Alliance
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.